T27423 |
GNE-375
|
1926989-06-1
|
99.32%
|
|
GNE-375 is a selective and potent BRD9 inhibitor (IC50: 5 nM).GNE-375 inhibits BRD4, TAF1, and CECR2, and can be used to study epigenetic resistance.
|
T6866 |
AUZ 454
|
853299-07-7
|
99.3%
|
|
AUZ 454 (K03861) is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respec...
|
T10738 |
Abemaciclib metabolite M20
|
2138499-06-4
|
99.29%
|
|
Abemaciclib metabolite M20 (CDK4/6-IN-4) is an active metabolite of Abemaciclib. Abemaciclib metabolite M20 is a selective CDK4/6 inhibitor and can be used for r...
|
T16324 |
Nimbolide
|
25990-37-8
|
99.28%
|
|
Nimbolide suppresses CDK4/CDK6 kinase activity. Nimbolide inhibits the NF-κB, Wnt, PI3K-Akt, MAPK, and JAK-STAT signaling pathways. Nimbolide causes apoptosis th...
|
T21314 |
Amsilarotene
|
125973-56-0
|
99.27%
|
|
Amsilarotene (TAC101) inhibits the phosphorylation of retinoblastoma gene product (RB) and increases the presence of 2 cyclin-dependent kinases (CDK) inhibitors ...
|
T10735 |
CDK4/6/1 Inhibitor
|
2099128-41-1
|
99.26%
|
|
CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM). CDK4/6 inhibitor is a class of compounds used for the treatment of some type...
|
T10729 |
Cdc7-IN-7
|
1402059-17-9
|
99.25%
|
|
Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase extracted from patent WO2019165473A1 (compound I-E).
|
T8866 |
GW779439X
|
551919-98-3
|
99.23%
|
|
GW779439X is an inhibitor of CDK.
|
T2506 |
AZD-5438
|
602306-29-6
|
99.23%
|
|
AZD-5438 is an effective inhibitor of CDK, for CDK1(IC50=16 nM), CDK2(IC50=6 nM), CDK9(IC50=20 nM).
|
T10436 |
AZD4573
|
2057509-72-3
|
99.23%
|
|
AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.
|
T6920 |
ON123300
|
1357470-29-1
|
99.22%
|
|
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
|
T6139 |
A-674563
|
552325-73-2
|
99.21%
|
|
A-674563 is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.
|
T2153 |
1-NM-PP1
|
221244-14-0
|
99.2%
|
|
1-NM-PP1 (PP1 Analog II) is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors.
|
T8325 |
SR-4835
|
2387704-62-1
|
99.19%
|
|
SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM), which disables triple-negative breast cancer (TNB...
|
T72029 |
CDK8-IN-13
|
918523-75-8
|
99.19%
|
|
CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727...
|
T14779 |
BRD7389
|
376382-11-5
|
99.17%
|
|
BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively.
|
T69742 |
SRX3177
|
2241237-51-2
|
99.16%
|
|
SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.
|
T21503 |
(E/Z)-Zotiraciclib
|
937270-47-8
|
99.12%
|
|
(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.
|
T3207 |
Briciclib
|
865783-99-9
|
99.11%
|
|
Briciclib (ON 014185) is a small molecule that suppresses cyclin D1 accumulation in Y cells.
|
T2709 |
TAK-901
|
934541-31-8
|
99.1%
|
|
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others....
|